Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy

  • Ziqiong Wang Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China https://orcid.org/0000-0002-9777-2650
  • Haiyan Ruan Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China; and Department of Cardiology, Traditional Chinese Medicine Hospital of Shuangliu District, Chengdu, China
  • Liying Li Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China
  • Xin Wei Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China; and Department of Cardiology and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
  • Ye Zhu Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China
  • Jiafu Wei Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China
  • Xiaoping Chen Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China
  • Sen He Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China https://orcid.org/0000-0002-0446-2865
DOI: https://doi.org/10.48101/ujms.v126.8124
Keywords: Systemic immuneinflammation index, all-cause mortality, hypertrophic cardiomyopathy, inflammation, risk stratification

Abstract

Background: This study investigates the predictive value of the systemic immune-inflammation index (SII), which was calculated as platelet × neutrophil/lymphocyte ratio, for all-cause mortality in patients with hypertrophic cardiomyopathy (HCM).

Methods: A total of 360 HCM patients were enrolled. They were divided into three groups based on the tertiles of baseline SII. The association between SII and all-cause mortality was analyzed.

Results: There were 53 HCM patients who died during a mean follow-up time of 4.8 years (min: 6 days and max: 10.8 years), and the mortality rate was 3.0 per 100 person years. The cumulative mortality rate was significantly different among the three tertiles of SII (P = 0.004), and the mortality rate in tertile 3 was much higher than that in the first two tertiles. In reference to tertile 1, the fully adjusted hazard ratios of all-cause mortality were 1.02 for the tertile 2 (95% confidence interval [CI]: 0.45–2.31, P = 0.966) and 2.31 for tertile 3 (95% CI: 1.10–4.87, P = 0.027). No significant interactions between SII and other variables were observed during subgroup analysis. The discriminative power was better for mid-term outcome than that for short-term or long-term outcomes. Sensitivity analyses including patients with normal platelet and white blood cell count have revealed similar results.

Conclusion: SII was a significant risk factor for all-cause mortality in HCM patients. However, the discriminative power was poor to moderate. It could be used in combination with other risk factors in mortality risk stratification in HCM.

Downloads

Download data is not yet available.

References


  1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54. doi: 10.1016/j.jacc.2015.01.019

  2. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655–68. doi: 10.1056/NEJMra1710575

  3. Cirino AL, Ho C. Hypertrophic cardiomyopathy overview. GeneReviews®, 1993; pp. 1–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/​20301725 [cited 1 August 2021].

  4. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785–91. doi: 10.1136/hrt.2005.068577

  5. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915–28. doi: 10.1016/j.jacc.2015.02.061

  6. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol. 2020;5:73–80. doi: 10.1001/jamacardio.2019.4534

  7. Zhu L, Zou Y, Wang Y, Luo X, Sun K, Wang H, et al. Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6:1–8. doi: 10.1161/JAHA.116.004529

  8. Ekizler FA, Cay S, Açar B, Tak BT, Kafes H, Ozeke O, et al. Monocyte to high-density lipoprotein cholesterol ratio predicts adverse cardiac events in patients with hypertrophic cardiomyopathy. Biomark Med. 2019;13:1175–86. doi: 10.2217/bmm-2019-0089

  9. Kuusisto J, Kärjä V, Sipola P, Kholová I, Peuhkurinen K, Jääskeläinen P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012;98:​1007–13. doi: 10.1136/heartjnl-2011-300960

  10. Ozyilmaz S, Akgul O, Uyarel H, Pusuroglu H, Gul M, Satilmisoglu MH, et al. The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev Port Cardiol. 2017;36:239–46. doi: 10.1016/j.repc.2016.09.014

  11. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9:3295–302. doi: 10.7150/jca.25691

  12. Zhong J-H, Huang D-H, Chen Z-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:75381–8. doi: 10.18632/oncotarget.​18856

  13. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50:1–11. doi: 10.1111/eci.13230

  14. Huang J, Zhang Q, Wang R, Ji H, Chen Y, Quan X, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit. 2019;25:9690–701. doi: 10.12659/MSM.919802

  15. Çırakoğlu ÖF, Yılmaz AS. Systemic immune-inflammation index is associated with increased carotid intima-media thickness in hypertensive patients. Clin Exp Hypertens. 2021;43:565–71. doi: 10.1080/10641963.2021.1916944

  16. Gok M, Kurtul A. A novel marker for predicting severity of acute pulmonary embolism: systemic immune-inflammation index. Scand Cardiovasc J. 2021;55:91–6. doi: 10.1080/14017431.2020.1846774

  17. Li LH, Chen CT, Chang YC, Chen YJ, Lee IH, How CK. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index in acute ischemic stroke: a STROBE-compliant retrospective study. Medicine. 2021;100:e26354. doi: 10.1097/MD.0000000000026354

  18. Zamorano JL, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79. doi: 10.1093/eurheartj/ehu284

  19. He S, Wang Z, Cheem TH, Liao H, Chen X, He Y. External validation of the model of thromboembolic risk in hypertrophic cardiomyopathy patients. Can J Cardiol. 2019;35:1800–6. doi: 10.1016/j.cjca.2019.05.035

  20. Wang Z, Liao H, Chen X, He S. Hyperuricemia: risk factor for thromboembolism in hypertrophic cardiomyopathy patients. Intern Emerg Med. 2020;15:1231–7. doi: 10.1007/s11739-020-02275-6

  21. Wang Z, Xu Y, Liao H, Chen X, He S. U-shaped association between serum uric acid concentration and mortality in hypertrophic cardiomyopathy patients. Ups J Med Sci. 2020;125:44–51. doi: 10.1080/03009734.2020.​1719245

  22. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212–22. doi: 10.1158/1078-0432.CCR-14-0442

  23. Liu Q, Li D, Berger A, Johns R, Gao L. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis. Sci Rep. 2017;7:1–10. doi: 10.1038/s41598-017-12289-4

  24. Haneuse S, VanderWeele T, Arterburn D. Using the e-value to assess the potential effect of unmeasured confounding in observational studies. JAMA.2019;321:602–3. doi: 10.1001/jama.2018.21554

  25. Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22:23–32. doi: 10.1016/j.semcancer.2011.12.004

  26. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52. doi: 10.1016/j.semcancer.2005.07.006

  27. Seo M, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, et al. P589Prognostic value of systemic immune-inflammation index in patients with chronic heart failure. Eur Heart J. 2018;39:70–1. doi: 10.1093/eurheartj/ehy564.P589

  28. Becker RC, Owens AP, Sadayappan S. Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. J Thromb Thrombolysis. 2020;49:177–83. doi: 10.1007/s11239-019-02026-1

  29. Wang Z, Zhao L, He S. Relation between neutrophil-to-lymphocyte ratio and mortality in patients with hypertrophic cardiomyopathy. Biomark Med. 2020;14:1693–701. doi: 10.2217/bmm-2020-0463

  30. Wang Z, Chen X, He S. Prognostic value of red blood cell distribution width for mortality in patients with hypertrophic cardiomyopathy. Clin Biochem. 2021;96:19–25. doi: 10.1016/j.clinbiochem.2021.07.002

  31. Marstrand P, Han L, Day S, Olivotto I, Ashley E, Michels M, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. Circulation. 2020;141:1371–83. doi: 10.1161/CIRCULATIONAHA.119.044366

  32. Fang L, Ellims A, Beale A, Taylor A, Murphy A, Dart A. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 2017;9:5063–73. doi: 10.1016/j.hlc.2017.06.155

Published
2021-12-03
How to Cite
Wang Z., Ruan H., Li L., Wei X., Zhu Y., Wei J., Chen X., & He S. (2021). Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy. Upsala Journal of Medical Sciences, 126(1). https://doi.org/10.48101/ujms.v126.8124
Issue
Vol. 126 (2021): Upsala J Med Sci
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.

Crossref
Scopus
Google Scholar
Europe PMC